These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 32853262)
1. Pseudo-colouring an ECG enables lay people to detect QT-interval prolongation regardless of heart rate. Alahmadi A; Davies A; Vigo M; Jay C PLoS One; 2020; 15(8):e0237854. PubMed ID: 32853262 [TBL] [Abstract][Full Text] [Related]
2. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology. Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421 [TBL] [Abstract][Full Text] [Related]
3. Can laypeople identify a drug-induced QT interval prolongation? A psychophysical and eye-tracking experiment examining the ability of nonexperts to interpret an ECG. Alahmadi A; Davies A; Vigo M; Jay C J Am Med Inform Assoc; 2019 May; 26(5):404-411. PubMed ID: 30848818 [TBL] [Abstract][Full Text] [Related]
4. Artificial Intelligence-Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device. Giudicessi JR; Schram M; Bos JM; Galloway CD; Shreibati JB; Johnson PW; Carter RE; Disrud LW; Kleiman R; Attia ZI; Noseworthy PA; Friedman PA; Albert DE; Ackerman MJ Circulation; 2021 Mar; 143(13):1274-1286. PubMed ID: 33517677 [TBL] [Abstract][Full Text] [Related]
5. Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. Prifti E; Fall A; Davogustto G; Pulini A; Denjoy I; Funck-Brentano C; Khan Y; Durand-Salmon A; Badilini F; Wells QS; Leenhardt A; Zucker JD; Roden DM; Extramiana F; Salem JE Eur Heart J; 2021 Oct; 42(38):3948-3961. PubMed ID: 34468739 [TBL] [Abstract][Full Text] [Related]
6. A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation. Simon ST; Lin M; Trinkley KE; Aleong R; Rafaels N; Crooks KR; Reiter MJ; Gignoux CR; Rosenberg MA PLoS One; 2024; 19(6):e0303261. PubMed ID: 38885227 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes. Krisai P; Vlachos K; Ramirez FD; Nakatani Y; Nakashima T; Takagi T; Kamakura T; Surget E; André C; Cheniti G; Welte N; Chauvel R; Tixier R; Duchateau J; Pambrun T; Derval N; Hocini M; Jaïs P; Haïssaguerre M; Sacher F J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2696-2701. PubMed ID: 32700358 [TBL] [Abstract][Full Text] [Related]
8. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938 [TBL] [Abstract][Full Text] [Related]
9. Data-driven drug-induced QT prolongation surveillance using adverse reaction signals derived from 12-lead and continuous electrocardiogram data. Choi BJ; Koo Y; Kim TY; Lim HS; Yoon D PLoS One; 2022; 17(1):e0263117. PubMed ID: 35100302 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046 [TBL] [Abstract][Full Text] [Related]
11. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. Markert M; Shen R; Trautmann T; Guth B J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956 [TBL] [Abstract][Full Text] [Related]
12. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Graff C; Andersen MP; Xue JQ; Hardahl TB; Kanters JK; Toft E; Christiansen M; Jensen HK; Struijk JJ Drug Saf; 2009; 32(7):599-611. PubMed ID: 19530746 [TBL] [Abstract][Full Text] [Related]
13. The phenotype characteristics of type 13 long QT syndrome with mutation in KCNJ5 (Kir3.4-G387R). Wang F; Liu J; Hong L; Liang B; Graff C; Yang Y; Christiansen M; Olesen SP; Zhang L; Kanters JK Heart Rhythm; 2013 Oct; 10(10):1500-6. PubMed ID: 23872692 [TBL] [Abstract][Full Text] [Related]
14. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. Kirchhof P; Franz MR; Bardai A; Wilde AM J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731 [TBL] [Abstract][Full Text] [Related]
15. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Isbister GK; Page CB Br J Clin Pharmacol; 2013 Jul; 76(1):48-57. PubMed ID: 23167578 [TBL] [Abstract][Full Text] [Related]
16. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Mayet S; Gossop M; Lintzeris N; Markides V; Strang J Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918 [TBL] [Abstract][Full Text] [Related]
17. Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients With Electrocardiographically Concealed Long QT Syndrome From the Surface 12-Lead Electrocardiogram. Bos JM; Attia ZI; Albert DE; Noseworthy PA; Friedman PA; Ackerman MJ JAMA Cardiol; 2021 May; 6(5):532-538. PubMed ID: 33566059 [TBL] [Abstract][Full Text] [Related]
18. Effect of atropine on QT prolongation and torsade de pointes induced by intracoronary acetylcholine in the long QT syndrome. Furushima H; Niwano S; Chinushi M; Yamaura M; Taneda K; Washizuka T; Aizawa Y Am J Cardiol; 1999 Mar; 83(5):714-8. PubMed ID: 10080424 [TBL] [Abstract][Full Text] [Related]